Aristotle® is a new blood test that can detect the molecular signatures of multiple cancers from a single sample of blood
to help you find cancer earlier. |
|
Early Cancer Detection Matters!
|
Everyone knows someone with Cancer. Unfortunately, almost 50% of people are diagnosed in the later stages when outcomes are poor(1). A late stage cancer diagnosis can be attributed to many factors such as postponing cancer screening, the fact that symptoms often don't appear until cancer has progressed, or a lack of convenient screening options.
Aristotle® is a multi-cancer test panel that uses mRNA technology to simultaneously detect multiple cancer signatures from a single sample of blood. Aristotle looks for the following cancer signatures:
ARISTOTLE® may be right for you if
|
Find out if You're a Candidate for the Aristotle® Multi-Cancer Blood Test
The Aristotle® test can be ordered for patients 18 and older. Aristotle® is not recommended for patients who have a current cancer diagnosis and are in treatment.
|
Why Early is Better
The chart below demonstrates the importance of early detection.(1)
Cancer Type |
5-Year Survival Rate When Found Early (1) (Localized) |
5-Year Survival Rate When Found Late (1) (Distant) |
Breast Cancer |
99% |
28% |
Ovarian Cancer |
93% |
31% |
Cervical Cancer |
92% |
17% |
Endometrial |
95% |
17% |
Colorectal Cancer |
91% |
14% |
Bladder Cancer |
96% |
6% |
Stomach Cancer |
70% |
6% |
Liver Cancer |
34% |
3% |
Prostate Cancer |
99% |
30% |
Our Science
|
Our underlying mRNA technology, The Sentinel Principle, has been validated in more than 9,000 patients and used by more than 100,000 patients in North America. (2) Aristotle was selected for online publication at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO).
Our laboratory in Richmond, VA is certified according to the Clinical Laboratory Improvement Amendment (CLIA) for high complexity laboratory testing through the Centers of Medicare and Medicaid Services (CMS). In addition, the lab is accredited through the College of American Pathologists (CAP). These certifications demonstrate our highest commitment to excellence in laboratory test processing and our passion for patient care.
|
|
Sources:
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
2. Aristotle: A single blood test for pan-cancer screening. Dempsey AA, Chao S, Stamatiou D, Pilcz T, Ying J, and Burakoff R; Journal of Clinical Oncology 2020; 38:15_suppl, e15037-e15037
Aristotle® was developed and its performance characteristics determined by Stage Zero Life Sciences, Inc. It has not been cleared or approved by the US Food and Drug Administration. This test is performed in a CLIA certified laboratory and is intended for clinical purposes. The ARISTOTLE® test must be ordered by and used only in consultation with a healthcare provider.
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
2. Aristotle: A single blood test for pan-cancer screening. Dempsey AA, Chao S, Stamatiou D, Pilcz T, Ying J, and Burakoff R; Journal of Clinical Oncology 2020; 38:15_suppl, e15037-e15037
Aristotle® was developed and its performance characteristics determined by Stage Zero Life Sciences, Inc. It has not been cleared or approved by the US Food and Drug Administration. This test is performed in a CLIA certified laboratory and is intended for clinical purposes. The ARISTOTLE® test must be ordered by and used only in consultation with a healthcare provider.
